NSE: ROSSARI | BSE: 543213

Mid-range Performer

Download real time

617.80 -0.75 (-0.12%)

36.49% Fall from 52W High

14,850 NSE+BSE Volume

NSE 28 Aug, 2025 12:17 PM (IST)

3,420.6

Market Cap

Above industry Median

0.7

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

25 Jul 2025

617.80

-0.12%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Deven Choksey

Rossari Biotech’s Q1FY26 revenue grew by 11.0% YoY (-6.2% QoQ) to INR 5,437 Mn., in-line with our estimates, the growth was entirely driven by volume expansion of 11.0% YoY.

Rossari Biotech Ltd. has lost -32.99% in the last 1 Year

Rossari Biotech Ltd.

22 Oct 2024

617.80

-0.12%

HPPC steady; outlook bright backed by capex, market gain; Buy

Buy: Rossari Biotech Ltd.

Target

Anand Rathi

We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Rossari Biotech Ltd. has an average target of 926.25 from 4 brokers.

Rossari Biotech Ltd.

22 Oct 2024

617.80

-0.12%

Rossari Biotech | Q2FY25 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. is trading below all available SMAs

Rossari Biotech Ltd.

21 Oct 2024

617.80

-0.12%

Exports drive revenue growth

Hold: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY25 HPPC revenue growth (+6.2% YoY) was hurt from softer demand and restricted ethylene oxide (EO) capacity.

Rossari Biotech Ltd. has lost -32.99% in the last 1 Year

Rossari Biotech Ltd.

13 Jun 2024

617.80

-0.12%

Diversified business mix; no major China competition; initiating, with a Buy

Buy: Rossari Biotech Ltd.

Anand Rathi

Rossari Biotech is a leading specialty chemicals manufacturing company, focusing on four core chemistries of enzymes, silicones, acrylics and surfactants. It caters to industries such as home and personal care, and performance chemicals (HPPC), textile specialty chemicals (TSC) and animal health and nutrition (AHN) products

Number of FII/FPI investors decreased from 82 to 65 in Jun 2025 qtr

Rossari Biotech Ltd.

01 May 2024

617.80

-0.12%

Rossari Biotech | Q4FY24 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC and capex to drive growth

Rossari Biotech Ltd. has an average target of 926.25 from 4 brokers.

Rossari Biotech Ltd.

24 Jan 2024

617.80

-0.12%

Rossari Biotech | Q3FY24 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

HPPC business and capex to drive growth

Number of FII/FPI investors decreased from 82 to 65 in Jun 2025 qtr

Rossari Biotech Ltd.

24 Oct 2023

617.80

-0.12%

Rossari Biotech | Q2FY24 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

Signs of a recovery in sight

Rossari Biotech Ltd. has lost -32.99% in the last 1 Year

Rossari Biotech Ltd.

24 Oct 2023

617.80

-0.12%

Volume jumps at the cost of margins

Sell: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY24 HPPC revenue (+21% YoY) was led by a volume push which has hurt prices and margins. Despite rise in utilisation from 50-55% to >75%, EBITDA margin dipped 100bp QoQ to 13.1%. It has chosen to play volume game for FY24 to drive utilisation, and expects to improve margins as plant utilisations stabilise at higher levels, which in our view can cap return ratio in near term.

Rossari Biotech Ltd. has lost -32.99% in the last 1 Year

Rossari Biotech Ltd.

01 Aug 2023

617.80

-0.12%

Performance acceleration may take some time

Sell: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q1FY24 revenue dipped 5.5% YoY to Rs4.1bn due to drop in raw material prices, while volume grew ~20% YoY. Gross profit margin dipped 10bps QoQ despite softening raw material prices as the company focused on growing volumes and driving operating leverage. EBITDA margin has improved 70bps QoQ to 14.1%. Rossari expects revenue growth of 12-14% and EBITDA margin at 14% for FY24 despite a weak Q1FY24.

Number of FII/FPI investors decreased from 82 to 65 in Jun 2025 qtr

VOTE: Is Rossari Biotech Ltd. worth buying?

68 Votes:

Buy 89.71%

Sell 4.41%

Hold 5.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf link